[ ImCheck Therapeutics raises $21.81M in Series A ]
ImCheck Therapeutics has raised $21.81 million in Series A funding.
Founded in 2015, ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly differentiated & diversified portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity.
The company intends to use the funds to advance its development plan of several drug-candidates and entry into the clinic by 2019.
|Founder / CEO||Benjamin CHARLES|
|Kurma Life Science Partners|
|Boehringer Ingelheim Venture Fund|